TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01475955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle PDT
Description: Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Treatment
Description: 10 J/cm2 blue light delivered at 10 mW/cm2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Treatment
Description: 10 J/cm2 blue light delivered at 10 mW/cm2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Treatment
Description: 10 J/cm2 blue light delivered at 10 mW/cm2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Treatment
Description: 10 J/cm2 blue light delivered at 10 mW/cm2

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blue Light Treatment
Description: 10 J/cm2 blue light delivered at 10 mW/cm2
Study: NCT04692727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McConnel patellar taping technique
Description: Individuals are placed in a supine position with their knees extended and the quadriceps relaxed. A 5 cm wide hypoallergenic band is applied transversely over the patella without affecting the position of the patella. Then, it is started at the lateral edge of the patella with a rigid tape. The tape is terminated at the medial femoral condyle after a medial pull and / or medial tilt to the patella.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral rotational taping technique
Description: This technique is applied in a standing position and hip extreme external rotation. Taping is started on the vastus medialis and is pulled diagonally from the anterior of the leg to the lateral and ends on the trochanter major.
Study: NCT03016143

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allantoic Split Inactivated Seasonal flu Vaccine
Description: Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allantoic Split Inactivated Seasonal flu Vaccine
Description: Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAXIGRIP
Description: Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAXIGRIP
Description: Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V
Study: NCT03739788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration of tablet and 15-minute intravenous BMS-986165 solution for infusion
Study: NCT00800462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin Cl
Description: 15 mg qd for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium Cl
Description: 20mg bid for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin Hydrogen Bromide (HBr)
Description: 15 mg qd for 3 months
Study: NCT01952522

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non weighted brace
Description: People will be given a brace with no weight they will have to wear all the day during three months.
Study: NCT02991378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's emotional and stress coping program
Description: Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
Study: NCT04032119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection
Description: Endoscopic submucosal dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection
Description: Endoscopic submucosal dissection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine
Study: NCT03719898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatininb is administered in tablet form. It is to be taken until disease progression, unacceptable toxicity or completion of 24 cycles. patients may continue to take brigatininb beyond 24 cycles if they are benefiting from the drug
Study: NCT03458598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: Rectus sheath block under ultrasound

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bilateral rectus sheath catheter
Description: A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral rectus sheath catheter
Description: A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Patient controlled opioid analgesia (PCA)
Description: Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient controlled opioid analgesia (PCA)
Description: Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Subcutaneous injection saline placebo
Description: Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
Study: NCT04715334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mollii suit
Description: The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
Study: NCT00393042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate
Description: 10, 20, 25-30 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate
Description: 10, 20, 25-30 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed Amphetamine Salts, ER
Description: 10, 20, 25-30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed Amphetamine Salts, ER
Description: 10, 20, 25-30
Study: NCT00251602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
Study: NCT00393042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: randomized placebo week during each 4 week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: randomized placebo week during each 4 week period
Study: NCT03777631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
Study: NCT02655770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00844519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
Study: NCT00735059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treatment with the dialyzer ELISIO 170H
Description: one week of three consecutive dialysis treatments, \> 3 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment with the dialyzer PES-170DS
Description: one week of three consecutive dialysis treatments, \> 3 hours
Study: NCT00844519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
Study: NCT02074020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blisibimod
Description: Administered via subcutaneous injection once per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection once per week
Study: NCT00798954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting coronary stent (Cypher)
Description: Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent (TAXUS)
Description: Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
Study: NCT03021915

Intervention type: OTHER
Group type: OTHER
Intervention: OvaPrime Treatment
Description: The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
Study: NCT01523197

Intervention type: DEVICE
Group type: OTHER
Intervention: BiPAP ventilation, auto-trilevel ventilation
Description: Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
Study: NCT02752477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-free general anesthetic
Description: An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional general anesthetic
Description: Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
Study: NCT03070652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NBO, Newborn behavioral observation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice as usual
Study: NCT04406831

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw
Study: NCT01034423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Capsules with omega-3 fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Capsules with omega-3 fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3
Description: Capsules with omega-3 fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sun flower oil
Description: Capsules with sun flower oil.
Study: NCT00251602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: One-time 0.25 ml/min infusion over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: One-time 0.25 ml/min infusion over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: One-time 0.25 ml/min infusion over 30 minutes
Study: NCT03487445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel 8 mg
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel 16 mg
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
Study: NCT01552876

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: A daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: A daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A
Description: A daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A
Description: A daily wear contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Filcon II 3
Description: a daily disposable
Study: NCT00933686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saizen®
Description: Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and Saizen®
Description: Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
Study: NCT03925532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Given SC
Study: NCT00362765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 160 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 160 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 2000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 2000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03698981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers Moving towards Empowerment (MME)
Description: MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a good woman and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children.
Study: NCT04594057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze and Postural Retraining Exercise
Description: Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaze and Postural Retraining Exercise
Description: Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training.
Study: NCT04733794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stoma reversal
Description: Patients will receive a comprehensive intervention to addresses bowel, sexual, and urinary dysfunction. Patients meeting appropriate inclusion criteria will be approached at a clinic visit with their surgeon. If they agree to participate, they will complete an initial baseline questionnaire. Questionnaires will be distributed on iPads during their clinic visit
Study: NCT00801307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spirometer
Description: According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spirometer
Description: According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spirometer
Description: According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
Study: NCT05053373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham electroacupuncture group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Study: NCT02655146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin 0.1
Description: a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2
Description: Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
Study: NCT01552876

Intervention type: DEVICE
Group type: OTHER
Intervention: Filcon II 3
Description: a daily disposable
Study: NCT00097539

Intervention type: BIOLOGICAL
Intervention: Somatrem

Intervention type: BIOLOGICAL
Intervention: Somatropin
Study: NCT01162850

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polypodium Leucotomos
Description: Oral capsule at 240 mg taken twice a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 240 mg Placebo taken orally twice daily created by company which manufactured active ingredient